Jazz Pharmaceuticals PLC reports results for the quarter ended June 30 - Earnings Summary

Jazz Pharmaceuticals

03/08/2026 22:39

Jazz Pharmaceuticals PLC JAZZ.OQ reported quarterly adjusted earnings of $5.71​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-8.25.  The mean expectation of eighteen analysts for the quarter was for earnings of $6.18 per share. Wall Street expected results to range from $5.53  to $7.08 per share.
Revenue rose 15.5% to $1.21 billion from a year ago; analysts expected $1.12 billion. 
Jazz Pharmaceuticals PLC's reported EPS for the quarter was $2.78​.
The company reported quarterly net income of $192.8 million.
Jazz Pharmaceuticals PLC shares had risen by 4.9% this quarter and gained 48.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.7% in the last three months.​ 
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $275.00, about 8.1% above its last closing price of $252.86
This summary was machine generated from LSEG data August 3 at 09:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
6.18
5.71
Missed
Mar. 31 2026 
4.57
6.34
Beat
Dec. 31 2025 
6.52
6.64
Beat
Sep. 30 2025 
5.92
8.13
Beat